Navigation Links
Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting
Date:5/15/2013

SAN DIEGO, May 15, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that clinical data from a Phase 1b trial of PEGPH20 (PEGylated Recombinant Human Hyaluronidase), an investigational new biologic, in combination with gemcitabine for treatment of patients with stage IV metastatic pancreatic cancer will be presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

In this Phase 1b study, 28 stage IV pancreatic ductal adenocarcinoma patients were treated with PEGPH20 in combination with gemcitabine. The overall response rate (CR+PR) was 42 percent* (n=24) as assessed by independent review at therapeutic dose levels of PEGPH20 (1.6 and 3.0 µg/kg). Treatment was generally well tolerated and the adverse event profile was consistent with those seen in previous studies of PEGPH20 as a single agent and as previously reported for gemcitabine alone. There was no evidence of new observed toxicity. Detailed clinical data, including CA 19-9 and pharmacodynamic results will be presented at the meeting.

Emerging data show that most pancreatic cancers surround themselves with a protective hyaluronan-rich matrix, which makes the disease difficult to treat and is itself an indicator of poor prognosis. PEGPH20 depletes this matrix component from the tumor and rapidly changes the tumor microenvironment and metabolism, which may render it more vulnerable to therapy as well as inhibit tumor growth.

"Data from this single arm Phase 1b study clearly reinforce the hypothesis of treating pancreatic cancer with PEGPH20 in conjunction with chemotherapeutic agents," said Joy Zhu , M.D., Ph.D., Vice President, Oncology Clinical Development,
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
2. Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
3. Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
4. Halozyme to Host Second Quarter Financial Results Conference Call
5. Halozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference Call
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
7. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
8. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market by ... Systems, Table-top Counters) by End-user (Inpatient Pharmacy Automation, ... to 2019” analyzes and studies the major market ... Asia-Pacific, and the Rest of the World (RoW). ... spread through 300 pages and in-depth TOC on ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Convey ... that a team from Iowa State University won first ... contest. Using a Convey HC-2ex, the team’s solution achieved ... times faster than the second place finisher. , Experts ... embarked upon the month long challenge, using a variety ...
(Date:10/20/2014)... ON , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: ... $1.7 million which brings Q3 orders to $5.8 million and provides ... control projects in North America and one ... continue to bid new projects at record levels," said Peter ... were higher at the end of Q3 than they have been ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... P. Horovitz , Ph.D., from its board of directors effective ... in August 2003, and served as its chairman from June ... on the Nominating and Corporate Governance and Audit Committees of ... more than a decade of dedicated service to GenVec, and ...
Breaking Biology Technology:Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2
... April 9, 2012 The University of Southern California Marshall ... announced its 6th Annual Marshall School of Business Leadership ... 11:00 am to 5:30 pm, at Los Angeles, newest landmark, ... (Logo: http://photos.prnewswire.com/prnh/20120409/LA84249LOGO ) A new dynamic ...
... WALTHAM, Mass., April 9, 2012   Syndax Pharmaceuticals, ... that investigators at The University of Texas MD ... have initiated a phase 1/2 study combining Syndax,s ... patients with locally recurrent or distant relapsed metastatic ...
... Carbon Limited today announces that they will be exhibiting at ... sheet of carbon just one atom thick, has been described ... University in 2004, for which the team was awarded a ... commercially. To support this work the UK Government recently ...
Cached Biology Technology:USC Marshall School of Business 6th Annual Leadership Summit 2USC Marshall School of Business 6th Annual Leadership Summit 3Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer 2Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer 3UK company to demonstrate their commercially effective graphene production process 2
(Date:10/15/2014)... and to an unexpected extent. The outbreak does not ... virus shows a new disease dynamic in regions, where ... the German National Academy of Sciences Leopoldina, acatech – ... Union of the German Academies of Sciences and Humanities ... , In the statement the academies call for the ...
(Date:10/15/2014)... Rosenstiel Award for Distinguished Work in Biomedical Science by ... of genomic instability and its implications for the immune ... to win the Rosenstiel Award; the first, Rod McKinnon, ... the Charles A. Janeway Professor of Pediatrics and Professor ... at the Howard Hughes Medical Institute at Boston Children,s ...
(Date:10/14/2014)... published in Cancer Research shows SIRT6—a protein ... cancers—can promote the development of skin cancers by turning ... of sun-damaged skin cells. , Previously considered protective, SIRT6 ... sirtuins that help regulate genomic stability and prevent some ... repair DNA damage, which can lead to cancer. This ...
Breaking Biology News(10 mins):Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
... OAK RIDGE, Tenn., Jan. 17, 2008 -- Oak ... work for the automotive supplier industry initiated through ... Technologies, or USAutoPARTs collaborative announced today at the ... Made up of a consortium of federal and ...
... Troy, N.Y. - Two theoretical physicists at Rensselaer ... the long-sought-after pathway that an HIV peptide takes ... years of biocomputation and simulation to uncover a ... penetrates the cell membrane. The discovery could help ...
... federal fishery agencies, regional management councils, universities, conservation groups, ... the Cocoanut Grove conference center in Santa Cruz, Calif., ... Groundfish Conference. The Western Groundfish Conference is ... Mary Yoklavich, research biologist with NOAA Fisheries Service. It ...
Cached Biology News:Oak Ridge to lead auto supplier R&D partnership 2Oak Ridge to lead auto supplier R&D partnership 3Researchers reveal HIV peptide's possible pathway into the cell 2Researchers reveal HIV peptide's possible pathway into the cell 3
muscle actin (HUC1-1)...
Anti-Mouse MIP-1g, Biotin (Polyclonal) (rabbit IgG)...
... Anti-NY-ESO-1, clone E978 ... NM_001327 Immunogen : ... Formulation: mouse ascites with ... Assurance: routinely evaluated by ...
... Chicken polyclonal to Opsin 1 ( Abpromise ... Antigen: Synthetic peptide: YEDSTHASIFTYT, corresponding to amino ... and synthetic peptide corresponding to amino acids 18/30 ... and used as immunogen. Entrez ...
Biology Products: